A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies

NCT07294300 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Hematological Malignancies

Interventions

DRUG: QLS2313

Sponsor

Qilu Pharmaceutical Co., Ltd.